J S Hong1, J Tian2, L H Wu2. 1. Department of Radiotherapy, First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian Province, PR China. 2. Department of Epidemiology and Health Statistics, Fujian Medical University, Fuzhou, Fuzhou, Fujian Province, PR China.
Abstract
PURPOSE: In the present study, we aimed to investigate the effects of chemotherapy-induced peripheral neurotoxicity (cipn) on psychological distress and sleep quality in cancer patients. METHODS: A total of 706 cancer patients were interviewed for the study. In the 4th week of treatment, patient cipn was measured using the Patient Neurotoxicity Questionnaire (pnq). The sleep quality and psychological distress of patients were measured using the Pittsburgh Sleep Quality Index (psqi), the Distress Thermometer (dt), and the Hospital Anxiety and Depression Scale (hads). Multiple logistic regression was applied to determine the independent effects of cipn on psychological distress and sleep disturbance in the patients. RESULTS: THESE CORRELATION COEFFICIENTS WERE OBTAINED: 0.387 (p < 0.0001) between the pnq total score and the dt score, 0.386 (p < 0.0001) between the pnq total score and the hads Depression score, 0.379 (p < 0.0001) between the pnq total score and the hads Anxiety score, and 0.399 (p < 0.0001) between the pnq total score and the psqi global score. The prevalence rates of distress, depression, anxiety, and poor sleep quality in the five pnq grades were statistically significantly different (p < 0.0001). After controlling for age, sex, education level, social supports, fatigue, disease stage, and tumour site, the pnq grades were found to be associated with depression (p < 0.0001), anxiety (p < 0.0001), and poor sleep quality (p < 0.0001). CONCLUSIONS: Chemotherapy-induced peripheral neurotoxicity negatively affects psychological distress and sleep quality in cancer patients treated with chemotherapy. High pnq grades were significantly associated with poor psychological status and sleep quality. Our results emphasize the importance of assessing peripheral neuropathies during chemotherapy and of adjusting treatment plans based on assessment results.
PURPOSE: In the present study, we aimed to investigate the effects of chemotherapy-induced peripheral neurotoxicity (cipn) on psychological distress and sleep quality in cancerpatients. METHODS: A total of 706 cancerpatients were interviewed for the study. In the 4th week of treatment, patientcipn was measured using the PatientNeurotoxicity Questionnaire (pnq). The sleep quality and psychological distress of patients were measured using the Pittsburgh Sleep Quality Index (psqi), the Distress Thermometer (dt), and the Hospital Anxiety and Depression Scale (hads). Multiple logistic regression was applied to determine the independent effects of cipn on psychological distress and sleep disturbance in the patients. RESULTS: THESE CORRELATION COEFFICIENTS WERE OBTAINED: 0.387 (p < 0.0001) between the pnq total score and the dt score, 0.386 (p < 0.0001) between the pnq total score and the hads Depression score, 0.379 (p < 0.0001) between the pnq total score and the hads Anxiety score, and 0.399 (p < 0.0001) between the pnq total score and the psqi global score. The prevalence rates of distress, depression, anxiety, and poor sleep quality in the five pnq grades were statistically significantly different (p < 0.0001). After controlling for age, sex, education level, social supports, fatigue, disease stage, and tumour site, the pnq grades were found to be associated with depression (p < 0.0001), anxiety (p < 0.0001), and poor sleep quality (p < 0.0001). CONCLUSIONS: Chemotherapy-induced peripheral neurotoxicity negatively affects psychological distress and sleep quality in cancerpatients treated with chemotherapy. High pnq grades were significantly associated with poor psychological status and sleep quality. Our results emphasize the importance of assessing peripheral neuropathies during chemotherapy and of adjusting treatment plans based on assessment results.
Authors: Barry V Fortner; Edward J Stepanski; Stephanie C Wang; Sarah Kasprowicz; H Heith Durrence Journal: J Pain Symptom Manage Date: 2002-11 Impact factor: 3.612
Authors: L E Carlson; M Angen; J Cullum; E Goodey; J Koopmans; L Lamont; J H MacRae; M Martin; G Pelletier; J Robinson; J S A Simpson; M Speca; L Tillotson; B D Bultz Journal: Br J Cancer Date: 2004-06-14 Impact factor: 7.640
Authors: Jennifer S Gewandter; Jenna Chaudari; Chinazom Ibegbu; Rachel Kitt; Jennifer Serventi; Joy Burke; Eva Culakova; Noah Kolb; Kathleen A Sluka; Mohamedtaki A Tejani; Nimish A Mohile Journal: Support Care Cancer Date: 2018-08-27 Impact factor: 3.603
Authors: Lisa M Mangus; Jamie L Dorsey; Rachel L Weinberg; Gigi J Ebenezer; Peter Hauer; Victoria A Laast; Joseph L Mankowski Journal: Toxicol Pathol Date: 2016-05-27 Impact factor: 1.902
Authors: Ilufredo Y Tantoy; Bruce A Cooper; Anand Dhruva; Janine Cataldo; Steven M Paul; Yvette P Conley; Marilyn Hammer; Kord M Kober; Jon D Levine; Christine Miaskowski Journal: Qual Life Res Date: 2018-04-21 Impact factor: 4.147
Authors: Christine Miaskowski; Steven M Paul; Judy Mastick; Mark Schumacher; Yvette P Conley; Betty Smoot; Gary Abrams; Kord M Kober; Steven Cheung; Jennifer Henderson-Sabes; Margaret Chesney; Melissa Mazor; Margaret Wallhagen; Jon D Levine Journal: Eur J Oncol Nurs Date: 2017-11-07 Impact factor: 2.398
Authors: Shirin ArdeshirRouhaniFard; Paul C Dinh; Patrick O Monahan; Sophie D Fossa; Robert Huddart; Chunkit Fung; Yiqing Song; Darren R Feldman; Robert J Hamilton; David J Vaughn; Neil E Martin; Christian Kollmannsberger; Lawrence Einhorn; Kurt Kroenke; Lois B Travis Journal: Cancer Epidemiol Biomarkers Prev Date: 2021-04-13 Impact factor: 4.254
Authors: Judith A Paice; Matt Mulvey; Michael Bennett; Patrick M Dougherty; John T Farrar; Patrick W Mantyh; Christine Miaskowski; Brian Schmidt; Thomas J Smith Journal: J Pain Date: 2016-11-21 Impact factor: 5.820